Annals of Oncology Advance Access published online on April 7, 2006
Annals of Oncology, doi:10.1093/annonc/mdl078
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Christie Hospital, Manchester, UK
* To whom correspondence should be addressed. Background: Phase III studies suggest that non-small-cell lung cancer (NSCLC) patients treated with cisplatin-docetaxel may have higher response rates and better survival compared with other platinum-based regimens. We report the final results of a randomised phase III study of docetaxel and carboplatin versus MIC or MVP in patients with advanced NSCLC. Patients and methods: Patients with biopsy proven stage III-IV NSCLC not suitable for curative surgery or radiotherapy were randomised to receive four cycles of either DCb (docetaxel 75 mg/m2, carboplatin AUC 6), or MIC/MVP (mitomycin 6 mg/m2, ifosfamide 3 g/m2 and cisplatin 50 mg/m2 or mitomycin 6 mg/m2, vinblastine 6 mg/m2 and cisplatin 50 mg/m2, respectively), 3 weekly. The primary end point was survival, secondary end points included response rates, toxicity and quality of life. Results: The median follow-up was 17.4 months. Overall response rate was 32% for both arms (partial response = 31%, complete response = 1%); 32% of MIC/MVP and 26% of DCb patients had stable disease. One-year survival was 39% and 35% for DCb and MIC/MVP, respectively. Two-year survival was 13% with both arms. Grade 3/4 neutropenia (74% versus 43%, P < 0.005), infection (18% versus 9%, P = 0.01) and mucositis (5% versus 1%, P = 0.02) were more common with DCb than MIC/MVP. The MIC/MVP arm had significant worsening in overall EORTC score and global health status whereas the DCb arm showed no significant change. Conclusions: The combination of DCb had similar efficacy to MIC/MVP but quality of life was better maintained.
Received October 27, 2005
Revised February 7, 2006
Accepted March 7, 2006
original article
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
R. Booton 1,
P. Lorigan 1 *,
H. Anderson 2,
S. Baka 1,
L. Ashcroft 1,
M. Nicolson 3,
M. O'Brien 4,
D. Dunlop 5,
K. O'Byrne 6,
V. Laurence 7,
M. Snee 8,
G. Dark 9,
and
N. Thatcher 1
2 Wythenshawe Hospital, Manchester, UK
3 Aberdeen Royal Infirmary, Aberdeen, UK
4 Royal Marsden Hospital, London, UK
5 Beetson Oncology Centre, Glasgow, UK
6 St James Hospital, Dublin, Eire
7 Poole Hospital, Poole, UK
8 Cookridge Hospital, Leeds, UK
9 Newcastle General Hospital, Newcastle, UK
P. Lorigan, E-mail: paul.lorigan{at}manchester.ac.uk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.-C. Ko, S.-C. Ciou, C.-M. Cheng, L.-H. Wang, J.-H. Hong, M.-Y. Jheng, S.-T. Ling, and Y.-W. Lin Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells Carcinogenesis, July 1, 2008; 29(7): 1448 - 1458. [Abstract] [Full Text] [PDF]
|
|